Home News Axel-sven Malkomes Named CFO of Cardior

Axel-sven Malkomes Named CFO of Cardior

Axel-sven Malkomes Named CFO of Cardior

Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the appointment of Axel-Sven Malkomes as Chief Financial Officer (CFO). Mr. Malkomes joins the executive leadership team to lead Cardior’s financial operations and planning, risk and compliance, investor relations, and information technology (IT) as the company continue to advance its pipeline and clinical development globally. Mr. Malkomes brings to Cardio nearly 30 years of life science industry experience from executive roles, investment banking, healthcare investing, and corporate development positions.

“Axel-Sven comes to Cardio at an exciting period of growth as we move our lead candidate CDR132L through the ongoing multi-national Phase 2 study in Europe, with the next step being the global expansion of our clinical and operational footprint with a focus on the US,” commented Claudia Ulbrich, MD, CEO and Co-Founder of Cardiol. “His decades of experience in the industry, with a strong track record across the financial side of biotech, will be an important addition to our team. Gaining this strength will enable us to build out our non-coding RNA-based therapeutics pipeline and establish an internationally leading position with this new therapeutic modality.”

“Axel-Sven is exceptionally qualified to ensure Cardior’s future corporate growth,” added Russell Greig, Ph.D., Chairman of Cardior’s Board. “His addition to the leadership team will add momentum for the company’s mission to bring disease-modifying treatments to heart disease patients to prolong and improve the quality of their lives.”

“Cardior is rapidly advancing a completely new approach that has significant potential to become a game-changer for heart disease treatment by identifying and counteracting the molecular mechanisms of ischemic-induced heart failure affecting large patient populations as well as rare cardiac diseases. I am impressed by the progress that the team has made to date and look forward to working closely with Claudia and her team to continue this positive momentum,” added Axel-Sven Malkomes, CFO of Cardior.

Axel-Sven Malkomes most recently held the position of CFO and CBO at Medigene AG, a listed German cell and gene therapy company, where he was responsible for finance, business development, investor relations, legal affairs, and IT. During his tenure, Axel played an integral role in strategically and financially reshaping the company, significantly advancing the cash reach as well as expanding the range of business development and licensing partnerships. Before Medigene, Mr. Malkomes held healthcare investment banking positions at Barclays and Société Générale. Prior to this, he co-headed European healthcare investments at UK private equity firm 3i Group plc, with over $20 billion in assets under management. Earlier, he held senior operational and corporate leadership positions at Merck KGaA, including a CEO position at a Merck KGaA group company. Mr. Malkomes started his career in investment banking at a range of banking institutions, namely Dresdner Bank, Sal. Oppenheim, which is now Deutsche Bank, Donaldson Lufkin Jenrette, which later became Credit Suisse, and Lehman Brothers, where he focused on a range of transactions in corporate finance, mergers and acquisitions, equity capital markets, and private equity for the healthcare industry.

Mr. Malkomes holds a business administration degree from the Otto-Friedrich University in Bamberg, completed senior executive management programs at INSEAD in Fontainebleau, Kellogg School of Management at Northwestern University in Chicago, and University of Science & Technology in Hong Kong, as well as gained extensive knowledge of the pharmaceutical industry and medicine through his professional activities and comprehensive further education.

Fiscal Stimulus Bolsters US Economic Growth in Q1, Fastest GDP Growth Since 2003

The second-fastest gross domestic product growth since the third quarter of 2003, reported by the Commerce Department on Thursday, left output just 0.9% shy of its level at the end of 2019.

US Economy Grew Robustly in First Quarter

GDP grew at a 6.4% annual rate in the quarter, leaving the economy within 1% of its peak.

Asia-Pacific Markets Broadly Lower As Investors Turn Cautious

Asia-Pacific markets struggled for gains Friday as investors turned cautious, despite a positive finish stateside in the previous session.

World Shares Near Record High on Strong US Economic Data and Earnings

US economic growth accelerated in the first quarter, fuelled by massive government aid.

How the US Won the Economic Recovery

I looked for a country that got the economic response to Covid-19 right. I found the US.

Barclays Boss Predicts Biggest Economic Boom Since 1948

The UK is about to experience its biggest economic boom since the aftermath of World War Two, according to Barclays boss Jes Staley. His upbeat...

Buying American Is Easier Said Than Done: Will Biden’s Plan Juice the US Economy?

Joe Biden and Donald Trump don't agree on much, but this much they do: We should buy American products. But that's easier said than done.

Silver Down As Dollar and Yields on Bonds Rose as US Economy Advanced

Benchmark U.S. 10-year Treasury yields hovered near a more than two-week high, increasing the opportunity cost of holding non-yielding bullion.

Yellen Doesn’t See Biden Plan Creating Inflation ‘Issue’

President Joe Biden’s economic plan is unlikely to create inflation pressure in the U.S. because the boost to demand will be spread over a decade, said Treasury Secretary Janet Yellen.

Inflationary Pressure, Hawkish Fed Official Remarks Keep US Stocks on Leash

Dow added 2.4%, the S&P 500 gained 5.6%, and the Nasdaq jumped 7%. Dow was down 0.54% at 33,875 while the S&P was down by 0.72%. Nasdaq was down by 0.85%.